



Peter A Fasching

Contact

Peter A Fasching

Publications (73)

Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. *Breast Cancer Res Treat* 2022

Ditsch N, Wöckel A, Untch M, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe H, Krug D, Kühn T, Kümmel S, Kolberg-Liedtke C, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Witzel I, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. *Breast Care (Basel)* 2022; 17:403-420.

Thill M, Luftner D, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. *Breast Care (Basel)* 2022; 17:421-429.

Kolberg-Liedtke C, Untch M, Thomssen C, Schneeweiss A, Müller V, Loibl S, Kühn T, Krug D, Janni W, Jackisch C, Huober J, Harbeck N, Haidinger R, Fasching P, Denkert C, Budach W, Brucker S, Luftner D, Thill M. Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference. *Breast Care (Basel)* 2022; 17:336-345.

Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jückerstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. *Cancers (Basel)* 2022; 14

Gerber B, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer J, Rhiem K, Fasching P, Nekljudova V, Loibl S, Hahn M, Klare P, Ataseven B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübke K, Heil J, Huober J, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. *Cancers (Basel)* 2022; 14

Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. *JAMA Oncol* 2022; 8:1010-1018.

Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübke K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. *Eur J Cancer* 2021

Ditsch N, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Möbus V, Maass N, Lux M, Luftner D, Schmidt M, Schneeweiss A, Thill M, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Loibl S, Kümmel S, Blohmer J, Bauerfeind I, Albert U, Krug D, Jackisch C, Kolberg-Liedtke C, Banys-Paluchowski M, Müller V, Janni W, Kühn T, Budach W, Dall P, Kreipe H, Huober J, Heil J, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Friedrich M. Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. *Geburtshilfe Frauenheilkd* 2021; 81:e31.

Ditsch N, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Möbus V, Maass N, Lux M, Luftner D, Schmidt M, Schneeweiss A, Thill M, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Loibl S, Kümmel S, Blohmer J, Bauerfeind I, Albert U, Krug D, Jackisch C, Kolberg-Liedtke C, Banys-Paluchowski M, Müller V, Janni W, Kühn T, Budach W, Dall P, Kreipe H, Huober J, Heil J, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Friedrich M. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. *Geburtshilfe Frauenheilkd* 2021; 81:1112-1120.

Friedl T, Tesch H, Mahner S, Brucker S, Heinrich G, Häberle L, Fasching P, Beckmann M, Coleman R, Janni W, Schneeweiss A, Jückstock J, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2021; 7:1149-1157.

Denkert C, Huober J, Rhiem K, Marme F, Reimer T, Schmidt M, Sinn B, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Solbach C, Lübke K, Seither F, Schneeweiss A, Link T, Blohmer J, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer E, Schmitt W, Hanusch C, Fasching P, Loibl S. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. *Lancet Oncol* 2021; 22:1151-1161.

Marme F, Loibl S, Lederer B, Tesch H, Hanusch C, Denkert C, Rey J, Rhiem K, Link T, Nekljudova V, Jackisch C, Fasching P, Huober J, Blohmer J, Schneeweiss A, Michel L, Solbach C, Untch M. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2021; 153:203-212.

Thill M, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Jackisch C, Friedrich M, Kolberg-Liedtke C, Fallenberg E, Fasching P, Fehm T, Kümmel S, Kühn T, Krug D, Kreipe H, Huober J, Heil J, Harbeck N, Gluz O, Gerber B, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. *Breast Care (Basel)* 2021; 16:214-227.

Ditsch N, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Fallenberg E, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Kolberg-Liedtke C, Friedrich M, Fasching P, Fehm T, Gerber B, Kümmel S, Kühn T, Krug D, Kreipe H, Jackisch C, Huober J, Heil J, Harbeck N, Gluz O, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. *Breast Care (Basel)* 2021; 16:228-235.

Untch M, Harbeck N, Thill M, Schneeweiss A, Müller V, Luftner D, Loibl S, Kühn T, Krug D, Kolberg-Liedtke C, Janni W, Jackisch C, Huober J, Haidinger R, Denkert C, Budach W, Brucker S, Fasching P, Thomssen C. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. *Geburtshilfe Frauenheilkd* 2021; 81:637-653.

Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodli S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. *Eur J Cancer* 2021; 148:159-170.

Furlanetto J, Lederer B, Gerber B, Zahm D, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Couch F, Schmutzler R, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer J, Lübke K, Untch M, Salat C, Huober J, Klare P, Fasching P. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. *Eur J Cancer* 2021; 145:44-52.

Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". *Breast* 2021; 55:138-139.

Huebner H, Beckmann M, Belleville E, Ruebner M, Untch M, Fasching P, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Müller V, Wallwiener M, Kurbacher C, Kuesters G, Hartkopf A, Lux M, Huober J, Volz B, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. *BMC cancer* 2020; 20:1091.

Tesch H, Luftner D, Schneeweiss A, Lux M, Fehm T, Overkamp F, Welslau M, Schulmeyer C, Kolberg H, Fasching P, Huober J, Thill M, Hartkopf A, Schütz F, Belleville E, Ettl J, Wöckel A, Müller V, Janni W. Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer. *Geburtshilfe Frauenheilkd* 2020; 80:1115-1122.

Huober J, Schütz F, Luftner D, Fehm T, Tesch H, Overkamp F, Welslau M, Schulmeyer C, Kolberg H, Fasching P, Thill M, Belleville E, Ettl J, Janni W, Lux M, Müller V, Hartkopf A, Schneeweiss A, Wöckel A. Update Breast Cancer 2020 Part 3 - Early Breast Cancer. *Geburtshilfe Frauenheilkd* 2020; 80:1105-1114.

De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial. *Breast Cancer Res* 2020; 22:111.

Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. *Cancers (Basel)* 2020; 12

Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. *Breast* 2020; 54:88-95.

Thill M, Mundhenke C, Moebus V, Maass N, Lux M, Luftner D, Loibl S, Kümmel S, Kühn T, Kreipe H, Park-Simon T, Reimer T, Rhiem K, Wöckel A, Witzel I, Thomssen C, Stickeler E, Solomayer E, Solbach C, Schneeweiss A, Schmidt M, Rody A, Huober J, Heil J, Banys-Paluchowski M, Albert U, Müller V, Janni W, Friedrich M, Krug D, Jackisch C, Kolberg-Liedtke C, Untch M, Bauerfeind I, Blohmer J, Budach W, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Diel I, Dall P, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. *Breast Care (Basel)* 2020; 15:294-309.

Luftner D, Fehm T, Tesch H, Overkamp F, Welslau M, Pöschke P, Kolberg H, Fasching P, Huober J, Thill M, Schütz F, Belleville E, Ettl J, Janni W, Wöckel A, Müller V, Hartkopf A, Schneeweiss A, Lux M. Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd 2020; 80:391-398.

Werutsky G, Nekljudova V, Vladimirova V, Kühn T, Rhiem K, Huober J, Krug D, Link T, Schneeweiss A, Gerber B, Jackisch C, Tesch H, Denkert C, Seiler S, Blohmer J, Fasching P, Hanusch C, Untch M, Loibl S. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer 2020; 130:92-101.

Schneeweiss A, Luftner D, Fehm T, Tesch H, Overkamp F, Welslau M, Pöschke P, Kolberg H, Fasching P, Thill M, Huober J, Belleville E, Ettl J, Janni W, Lux M, Wöckel A, Müller V, Hartkopf A, Schütz F. Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd 2020; 80:277-287.

Karn T, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Gerber B, Holtrich U, Müller V, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marme F, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res 2020; 26:1896-1904.

Massa C, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Weber K, Huober J, Marme F, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer 2020; 8

Sinn B, Denkert C, Seliger B, von Minckwitz G, Huober J, Ataseven B, Stickeler E, Schem C, Marme F, Klauschen F, Taube E, Karn T, Blohmer J, Symmans W, Fasching P, Schmitt W, Weber K, Loibl S. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Res 2019; 21:142.

Witzel I, Untch M, Stickeler E, Schem C, Marme F, Mackelenbergh M, Karn T, Huober J, Lück H, Weber K, Denkert C, Fasching P, Wirtz R, Loibl S, Müller V. Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. Br J Cancer 2019; 121:1009-1015.

Luftner D, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Kolberg H, Jackisch C, Bauerfeind I, Braun M, Brucker S, Fasching P, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Thill M. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel) 2019; 14:315-324.

Wöckel A, Rhiem K, Nitz U, Mundhenke C, Müller-Schimpfle M, Möbus V, Maass N, Lux M, Luftner D, Loibl S, Rody A, Schmidt M, Witzel I, Wenz F, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Schneeweiss A, Kümmel S, Kühn T, Krug D, Dall P, Budach W, Blohmer J, Bauerfeind I, Albert U, Janni W, Müller V, Thill M, Untch M, Diel I, Fasching P, Kreipe H, Kolberg-Liedtke C, Jackisch C, Huober J, Harbeck N, Hanf V, Gerber B, Friedrich M, Fehm T, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14:224-245.

Ditsch N, Schmidt M, Rody A, Rhiem K, Nitz U, Mundhenke C, Müller-Schimpfle M, Möbus V, Maass N, Lux M, Schneeweiss A, Schütz F, Wöckel A, Witzel I, Wenz F, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Luftner D, Loibl S, Kümmel S, Diel I, Dall P, Budach W, Blohmer J, Bauerfeind I, Albert U, Müller V, Janni W, Jackisch C, Fasching P, Fehm T, Kühn T, Krug D, Kreipe H, Kolberg-Liedtke C, Huober J, Harbeck N, Hanf V, Gerber B, Friedrich M, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14:247-255.

Furlanetto J, Mehta K, Nekljudova V, Untch M, Thomssen C, Hanusch C, Lück H, Nitz U, Bauerfeind I, Gerber B, Fasching P, Huober J, Schneeweiss A, Möbus V, Lederer B, von Minckwitz G, Loibl S. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. *Breast Cancer* 2019; 26:826-834.

Untch M, Kühn T, Luftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching P, Kolberg-Liedtke C, Kolberg H, Thomssen C, Bauerfeind I, Braun M, Brucker S, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). *Geburtshilfe Frauenheilkd* 2019; 79:591-604.

Kolberg H, Wallwiener M, Overkamp F, Tesch H, Ettl J, Luftner D, Müller V, Schütz F, Fasching P, Taran F, Hartkopf A, Janni W, Schneeweiss A, Fehm T, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux M, Brucker S. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. *Geburtshilfe Frauenheilkd* 2019; 79:470-482.

Untch M, Hackmann J, Blohmer J, Rhiem K, Schmitt W, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Hanusch C, Just M, Fasching P, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. *J Clin Oncol* 2019; 37:2226-2234.

Laakmann E, Ingold-Heppner B, Huober J, Hanusch C, Jackisch C, Reinisch M, Untch M, von Minckwitz G, Nekljudova V, Müller V, Blohmer J, Zahm D, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, Klare P, Schneeweiss A, Salat C, Loibl S. Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. *Breast Cancer Res* 2019; 21:60.

Denkert C, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B, Dietel M, Fasching P, Colleoni M, Blohmer J, Mehta K, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Solbach C, Thürlimann B, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. *Breast Cancer Res Treat* 2019; 176:557-568.

Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. *Cancers (Basel)* 2018; 11

Deniz M, Andergassen U, Steidl J, Trapp E, Fasching P, Häberle L, Beckmann M, Schneeweiss A, Schrader I, Janni W, Rack B, Jueckstock J, Kost B, deGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer E, Aivazova-Fuchs V, Weissenbacher T, Friedl T. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. *Breast* 2018; 44:81-89.

Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Sinn H, Hirsmüller S, Tesch H, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Fasching P, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücken A, Nöthlings U, Müller V, Möbus V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Krockenberger M, Wöckel A, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kühn T, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Stangl S, Heuschmann P, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, König K, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henschler U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Bartsch H, Petersen C, Siedentopf F, Hahne A, Kreipe H, Knoefel W, Denking M, Brucker S, Luftner D, Kubisch C, Gerlach C, Lebeau A, Paradies K. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. *Geburtshilfe Frauenheilkd* 2018; 78:927-948.

Fasching P, Huober J, Liedtke C, Weinshilboum R, Wang L, Ingle J, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, von Minckwitz G, Fehm T, Blohmer J, Costa S, Loibl S, Hu C, Hart S, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Couch F. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. *J Clin Oncol* 2018; 36:2281-2287.

Untch M, Loibl S, Nekljudova V, Fehm T, Hauschild M, Blohmer J, Kunz G, Jackisch C, Solbach C, Huober J, Hanusch C, Eggemann H, Tesch H, Fasching P, Rezai M, Schem C, Gerber B, von Minckwitz G, GBG and the AGO-B Study Group. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). *J Clin Oncol* 2018; 36:1308-1316.

Polasik A, Janni W, Huober J, Müller V, Schneeweiss A, Fasching P, Hartkopf A, Rack B, Friedl T, De Gregorio A, Schochter F, Tzschaschel M, Fehm T. Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?. *Geburtshilfe Frauenheilkd* 2017; 77:1291-1298.

Lux M, Wallwiener M, Müller V, Beckmann M, Belleville E, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Luftner D, Huober J, Ettl J, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Fasching P. Update Breast Cancer 2017 - Implementation of Novel Therapies. *Geburtshilfe Frauenheilkd* 2017; 77:1281-1290.

Denkert C, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching P, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Kümmel S, Pfitzner B, Karn T, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt W, Blohmer J, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol* 2017; 19:40-50.

De Gregorio A, Janni W, Fasching P, Taran F, Hartkopf A, Jaeger B, Meier-Stiegen F, Pantel K, Schneeweiss A, Mueller V, Riethdorf S, Alunni-Fabbroni M, Trapp E, Rack B, De Gregorio N, Scholz C, Huober J, Friedl T, Fehm T. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. *JCO Precis Oncol* 2017; 1:1-12.

Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. *Breast* 2017; 37:42-51.

Hahnen E, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Neidhardt G, Schem C, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching P, Blohmer J, Jackisch C, Paepke S, Gerber B, Kümmel S, Schmutzler R. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. *JAMA Oncol* 2017; 3:1378-1385.

van Mackelenbergh M, Weber K, von Minckwitz G, Untch M, Schneeweiss A, Müller V, Kümmel S, Blohmer J, Fasching P, Huober J, Hanusch C, Jackisch C, Stickeler E, Marme F, Schem C, Karn T, Nekljudova V, Denkert C, Loibl S. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. *Breast Cancer Res Treat* 2017; 167:59-71.

Kümmel S, Burchardi N, von Minckwitz G, Fasching P, Klare P, Engels K, Denkert C, Schneeweiss A, Jackisch C, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Blohmer J, Untch M, Schem C, Huober J, Paepke S, Loibl S. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). *Eur J Cancer* 2017; 84:1-8.

Untch M, Luftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Kühn T, Janni W, Gerber B, Huober J, Jackisch C, Schneeweiss A, Brucker S, Dall P, Denkert C, Fasching P, Fehm T, Liedtke C. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). *Geburtshilfe Frauenheilkd* 2017; 77:633-644.

Loibl S, Untch M, von Minckwitz G, Mehta K, Jackisch C, Tiemann K, Fasching P, Pfitzner B, Eidtmann H, Hartmann A, Lederer B, Furlanetto J, Klimowicz A, Huober J, Darb-Esfahani S, Denkert C. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. *Clin Cancer Res* 2016; 22:2675-83.

Widschwendter P, Jueckstock J, Neugebauer J, Trapp E, Fasching P, Beckmann M, Schneeweiss A, Schrader I, Rack B, Janni W, Andergassen U, Kost B, Friedl T, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Scholz C. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. *Breast Cancer Res* 2015; 17:129.

Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilbom R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. *Int J Cancer* 2015; 137:2981-8.

Jackisch C, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Loibl S, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Untch M. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. *Breast Care (Basel)* 2015; 10:211-9.

Salmen J, Sohn C, Fehm T, Mohrmann S, Loehberg C, Hein A, Schulz-Wendtland R, Hartkopf A, Brucker S, Wallwiener D, Friese K, Hartmann A, Beckmann M, Janni W, Rom J, Heil J, Neugebauer J, Fasching P, Häberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orłowska-Volk M, Windfuhr-Blum M, Rack B. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. *Breast Cancer Res Treat* 2014; 148:143-51.

Loibl S, Fasching P, Andre F, Lindner J, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Pfitzner B, Huober J, Heinrichs C, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm D, Sinn P, Khandan F, Eidtmann H, Dohnal K, Denkert C. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. *J Clin Oncol* 2014; 32:3212-20.

von Minckwitz G, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching P, Sinn B, Engels K, Mehta K, Nekljudova V, Klare P, Eidtmann H, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer J, Jackisch C, Paepke S, Gerber B, Zahm D, Kümmel S, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol* 2014; 15:747-56.

Loibl S, Denkert C, Hilfrich J, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Nekljudova V, von Minckwitz G, Huober J, Kümmel S, Volz C, Mau C, Blohmer J, Costa S, Eidtmann H, Fasching P, Gerber B, Hanusch C, Jackisch C, Untch M. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. *Breast Cancer Res Treat* 2014; 144:153-62.

von Minckwitz G, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching P, Karn T, Müller V, Jackisch C, Huober J, Hilfrich J, Tesch H, Schmitt W, Loibl S, Müller B, Blohmer J, Sinn B, Eidtmann H, Eiermann W, Gerber B, Denkert C. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. *Clin Cancer Res* 2013; 19:4521-31.

Huober J, Kümmel S, Mau C, Jackisch C, Khandan F, Costa S, Krabisch P, Loibl S, Nekljudova V, Untch M, Höß C, Gerber B, Fasching P, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer J, Tesch H, Minckwitz G. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). *Eur J Cancer* 2013; 49:2284-93.

Denkert C, von Minckwitz G, Tesch H, Hansmann M, Reinisch M, Engels K, Sinn B, Fasching P, Mehta K, Solbach C, Brase J, Darb-Esfahani S, Kronenwett R, Prinzler J, Loibl S, Huober J, Untch M. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. *Breast Cancer Res* 2013; 15:R11.

von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol* 2012; 30:1796-804.

von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med* 2012; 366:299-309.

Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. *Lancet Oncol* 2012; 13:135-44.

von Minckwitz G, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jackisch C, Hilfrich J, Mehta K, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. *Breast Cancer Res Treat* 2010; 125:145-56.

von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. *J Clin Oncol* 2010; 28:2015-23.

Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. *J Clin Oncol* 2010; 28:2024-31.

Projects (0)

No results found.

Kantonsspital St.Gallen
Rorschacher Strasse 95
CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch